drugset / Trial / NCT00504231
Intradermal Influenza Vaccine Study in Elders
Phase 2
Completed
257 enrolled
PATH
Seattle Institute for Biomedical and Clinical Research · collabVA Puget Sound Health Care System · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
This randomized trial compared the immunogenicity of 60% dose intradermal (ID) influenza vaccination to standard intramuscular (IM) vaccination of full-dose or 60% dose vaccine. Pre- and postvaccination measurements in the hemagglutination inhibition antibody (HAI) titer were compared. Participants who received reduced-dose vaccine were revaccinated with full-dose IM vaccine.
Timeline
- Start
- 2007-09
- Primary completion
- 2008-01
- Completion
- 2008-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Influenza Virus Vaccine | Vaccine | 0.15 ml | Intravenous |
| Subject | Influenza Virus Vaccine | Vaccine | 0.3 ml | Intravenous |
| Subject | Influenza Virus Vaccine | Vaccine | 0.5 ml | Intravenous |